| 128 | Humans |
| 116 | Influenza |
| 100 | Human |
| 84 | Influenza, Human (epidemiology) |
| 83 | Public health |
| 76 | France |
| 70 | Influenza A |
| 69 | Vaccine |
| 53 | Vaccination |
| 51 | Influenza, Human (prevention & control) |
| 49 | Prevention |
| 49 | Adult |
| 48 | H1N1 influenza |
| 48 | Epidemiology |
| 47 | Female |
| 45 | Influenza A virus |
| 39 | Male |
| 38 | Middle Aged |
| 37 | Avian influenza |
| 34 | Medicine |
| 34 | Child |
| 33 | Pandemics |
| 33 | Animals |
| 32 | Epidemic |
| 31 | Infection |
| 30 | COVID-19 |
| 29 | Young Adult |
| 28 | Influenza, Human (virology) |
| 28 | Immunoprophylaxis |
| 28 | Adolescent |
| 27 | Antiviral |
| 26 | France (epidemiology) |
| 26 | Aged |
| 23 | Disease Outbreaks |
| 22 | Sanitary surveillance |
| 22 | Influenza A (H1N1) |
| 21 | Disease Outbreaks (prevention & control) |
| 20 | Resuscitation |
| 19 | Microbiology |
| 19 | Europe |
| 18 | Influenza A Virus, H1N1 Subtype (immunology) |
| 18 | Child, Preschool |
| 18 | 2009 |
| 17 | Pandemic |
| 17 | Influenza Vaccines (administration & dosage) |
| 17 | Infant |
| 16 | pandemic |
| 16 | Treatment |
| 16 | Pregnancy |
| 16 | Intensive care |
| 16 | Influenza Vaccines (immunology) |
| 15 | Surveillance |
| 14 | Virus |
| 14 | Seasons |
| 14 | Influenza, Human (transmission) |
| 14 | Influenza A Virus, H1N1 Subtype (isolation & purification) |
| 13 | Influenzavirus |
| 13 | Influenza, Human (diagnosis) |
| 13 | Influenza virus |
| 13 | Influenza A Virus, H1N1 Subtype |
| 13 | Aged, 80 and over |
| 12 | Vaccination (statistics & numerical data) |
| 12 | Swine |
| 12 | Influenza, Human (immunology) |
| 12 | Antiviral Agents (therapeutic use) |
| 11 | Toxicity |
| 11 | Review |
| 11 | Respiratory distress |
| 11 | Influenza, Human (mortality) |
| 11 | Influenza Vaccines |
| 11 | HIV |
| 10 | Risk factor |
| 10 | Risk Factors |
| 10 | Prospective Studies |
| 10 | Pediatrics |
| 10 | Influenza, Human (drug therapy) |
| 10 | Influenza A Virus, H1N1 Subtype (genetics) |
| 10 | Infant, Newborn |
| 10 | Immunological adjuvant |
| 10 | Hospital |
| 10 | H1N1 |
| 10 | French |
| 10 | Covid-19 |
| 10 | Acute |
| 9 | Viral disease |
| 9 | Respiratory disease |
| 9 | Pneumonia |
| 9 | Oseltamivir |
| 9 | Obesity |
| 9 | Intensive care unit |
| 9 | Influenza A Virus, H1N1 Subtype (pathogenicity) |
| 9 | Incidence |
| 9 | Immune response |
| 9 | Global Health |
| 9 | Epidemics |
| 9 | Diagnosis |
| 9 | China |
| 9 | Army |
| 9 | AIDS |
| 8 | covid-19 |
| 8 | Vaccination coverage |
| 8 | Travel |
| 8 | Immunogenicity |
| 8 | Immunization |
| 8 | Coronavirus |
| 8 | Chemotherapy |
| 7 | virus |
| 7 | epidemic |
| 7 | Zoonosis |
| 7 | World |
| 7 | Tropical medicine |
| 7 | Seasonal variation |
| 7 | SARS-CoV-2 |
| 7 | Risk |
| 7 | Risk management |
| 7 | Public Health |
| 7 | Pandemics (prevention & control) |
| 7 | Mortality |
| 7 | Military environment |
| 7 | Influenzavirus A(H5N1) |
| 7 | Influenzavirus A(H1N1) |
| 7 | Health Policy |
| 7 | HIV-1 |
| 7 | Emerging disease |
| 7 | Clinical management |
| 6 | public health |
| 6 | mobility |
| 6 | health |
| 6 | geography |
| 6 | World Health Organization |
| 6 | Transmission |
| 6 | Time Factors |
| 6 | Recommendation |
| 6 | Population Surveillance |
| 6 | Mouse |
| 6 | Influenza A Virus, H5N1 Subtype (immunology) |
| 6 | Influenza A Virus, H1N1 Subtype (physiology) |
| 6 | Genetic reassortment |
| 6 | Computer Simulation |
| 6 | Anesthesia |
| 5 | pollution |
| 5 | coronavirus |
| 5 | Wuhan |
| 5 | Veterinary |
| 5 | Vaccines |
| 5 | United States |
| 5 | Severity of Illness Index |
| 5 | Severe acute respiratory syndrome |
| 5 | Respiratory tract |
| 5 | Pneumology |
| 5 | Physician |
| 5 | Models, Statistical |
| 5 | Modeling |
| 5 | Mexico |
| 5 | Italy |
| 5 | Influenza, Human (complications) |
| 5 | Humoral immunity |
| 5 | Hospitalization |
| 5 | Hemagglutinin |
| 5 | Hemagglutinin Glycoproteins, Influenza Virus (genetics) |
| 5 | Hemagglutination Inhibition Tests |
| 5 | Flulike syndrome |
| 5 | Exo-α-sialidase |
| 5 | Evolution |
| 5 | Europe (epidemiology) |
| 5 | Efficiency |
| 5 | Detection |
| 5 | Decision Making |
| 5 | Cross-Sectional Studies |
| 5 | Comparative study |
| 5 | Cohort study |
| 5 | Cohort Studies |
| 5 | Cell Line |
| 5 | Case history |
| 5 | Bioterrorism |
| 5 | Avian influenzavirus |
| 5 | Attitude of Health Personnel |
| 5 | Asia |
| 5 | Arbovirus |
| 5 | Age Distribution |
| 5 | Humans |
| 4 | vulnerability |
| 4 | vaccination |
| 4 | urban economy |
| 4 | transport |
| 4 | territories |
| 4 | telework |
| 4 | obesity |
| 4 | local development |
| 4 | internal migration |
| 4 | influenza |
| 4 | economy |
| 4 | economic geography |
| 4 | cities |
| 4 | Zoonoses (virology) |
| 4 | Zika virus |
| 4 | Virology |
| 4 | Treatment Outcome |
| 4 | Serology |
| 4 | Sensitivity and Specificity |
| 4 | Reverse transcription polymerase chain reaction |
| 4 | Reunion island |
| 4 | Retrospective Studies |
| 4 | Prognosis |
| 4 | Pig |
| 4 | Patient |
| 4 | Pathogenicity |
| 4 | Oseltamivir (therapeutic use) |
| 4 | Narcolepsy |
| 4 | Mutation |
| 4 | Models, Theoretical |
| 4 | Models, Biological |
| 4 | Mice |
| 4 | Malignant tumor |
| 4 | Influenzavirus A |
| 4 | Influenza, Human (blood) |
| 4 | Influenza viruses |
| 4 | Influenza in Birds (epidemiology) |
| 4 | Influenza Vaccines (adverse effects) |
| 4 | Influenza A virus (classification) |
| 4 | Immunology |
| 4 | History, 20th Century |
| 4 | Health staff |
| 4 | Health policy |
| 4 | Health care staff |
| 4 | Hazard |
| 4 | Emergence |
| 4 | Dogs |
| 4 | Disease Outbreaks (statistics & numerical data) |
| 4 | Complication |
| 4 | Birds |
| 4 | Antibiotic |
| 4 | Aids |
| 4 | Age |
| 4 | Age Factors |
| 4 | Africa |
| 4 | Adaptation |
| 3 | value chains |
| 3 | telecommunications |
| 3 | surveillance |
| 3 | risk |
| 3 | repatriation |
| 3 | pandémie |
| 3 | lockdown |
| 3 | international migration |
| 3 | influenza A virus |
| 3 | floating population |
| 3 | epidemiology |
| 3 | containment |
| 3 | confinement |
| 3 | circular economy |
| 3 | Zoonoses (epidemiology) |
| 3 | Yersinia pestis |
| 3 | Virulence |
| 3 | Vibrio cholerae |
| 3 | Use |
| 3 | United States (epidemiology) |
| 3 | Taiwan |
| 3 | Survey |
| 3 | Subtype |
| 3 | Socioeconomic Factors |
| 3 | Simulation |
| 3 | Severe |
| 3 | Sentinel Surveillance |
| 3 | Sanitary program |
| 3 | Safety |
| 3 | Risk perception |
| 3 | Rhinovirus (isolation & purification) |
| 3 | Reverse Transcriptase Polymerase Chain Reaction |
| 3 | Reunion (epidemiology) |
| 3 | Result |
| 3 | Respiratory Distress Syndrome, Adult (therapy) |
| 3 | Resistance |
| 3 | Recipient |
| 3 | Reassortant Viruses (pathogenicity) |
| 3 | Reassortant Viruses (genetics) |
| 3 | Real time |
| 3 | Quarantine |
| 3 | Public health organization |
| 3 | Prospective |
| 3 | Poultry |
| 3 | Polymerase chain reaction |
| 3 | Phylogeography |
| 3 | Pathogenic |
| 3 | Pathogenesis |
| 3 | Pandemic influenza |
| 3 | Pandemic Risk |
| 3 | Oxygenation |
| 3 | Oxygen |
| 3 | Obstetrics |
| 3 | Neutralization Tests |
| 3 | Neuraminidase inhibitor |
| 3 | Models |
| 3 | Military |
| 3 | Military Personnel |
| 3 | Microorganism |
| 3 | Mathematical model |
| 3 | Management |
| 3 | Knowledge |
| 3 | Interviews as Topic |
| 3 | Influenza, Human (therapy) |
| 3 | Influenza, Human (history) |
| 3 | Influenza in Birds (transmission) |
| 3 | Influenza Vaccines (therapeutic use) |
| 3 | Influenza A virus (physiology) |
| 3 | Influenza A virus (pathogenicity) |
| 3 | Influenza A virus (genetics) |
| 3 | Influenza A Virus |
| 3 | Influenza A Virus, H5N1 Subtype |
| 3 | Influenza A Virus, H5N1 Subtype (genetics) |
| 3 | Influenza A Virus, H1N1 Subtype (growth & development) |
| 3 | Infectious diseases |
| 3 | Indian Ocean |
| 3 | In vitro |
| 3 | Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use) |
| 3 | Human immunodeficiency virus |
| 3 | History |
| 3 | Hemorrhagic fever |
| 3 | Hemagglutinin Glycoproteins, Influenza Virus (metabolism) |
| 3 | Hemagglutinin Glycoproteins, Influenza Virus (immunology) |
| 3 | Health service |
| 3 | Health and environment |
| 3 | Health Knowledge, Attitudes, Practice |
| 3 | HIV/AIDS |
| 3 | H5N1 |
| 3 | H1N1 Subtype |
| 3 | Gynecology |
| 3 | Genotype |
| 3 | Genetic vaccine |
| 3 | General practitioner |
| 3 | General practice |
| 3 | Follow-Up Studies |
| 3 | Fatal course |
| 3 | Extracorporeal Membrane Oxygenation (methods) |
| 3 | Evaluation |
| 3 | Estimation |
| 3 | Emergency |
| 3 | Drug |
| 3 | Disease |
| 3 | Disease Outbreaks (history) |
| 3 | Disease Models, Animal |
| 3 | Disaster |
| 3 | Decision aid |
| 3 | Comorbidity |
| 3 | Communicable Disease Control (methods) |
| 3 | Clinical trial |
| 3 | Clinical biology |
| 3 | Chemoprophylaxis |
| 3 | Check |
| 3 | Cataplexy |
| 3 | Cameroon |
| 3 | Calcitonin (blood) |
| 3 | Bibliographic review |
| 3 | Bacteriosis |
| 3 | Aves |
| 3 | Antibody |
| 3 | Antibodies |
| 3 | Animal |
| 3 | Amino Acid Sequence |
| 3 | Aedes aegypti |
| 3 | Pandemics |
| 2 | vaccine |
| 2 | outbreak |
| 2 | origin |
| 2 | neutralizing antibodies |
| 2 | membrane fusion |
| 2 | mathematical modelling |
| 2 | influenza virus |
| 2 | inflammation |
| 2 | immunity |
| 2 | hepatitis e virus |
| 2 | global change |
| 2 | flu |
| 2 | experimental evolution |
| 2 | epidemics |
| 2 | epidemic model |
| 2 | enseignement à distance |
| 2 | demography |
| 2 | crise sanitaire |
| 2 | covid-19 pandemic |
| 2 | conditions de logement |
| 2 | age |
| 2 | Zoonoses (transmission) |
| 2 | Zanamivir |
| 2 | Workforce |
| 2 | Woman |
| 2 | Winter |
| 2 | Virus Diseases |
| 2 | Virulence Factors (metabolism) |
| 2 | Virulence Factors (genetics) |
| 2 | Viral membrane fusion |
| 2 | Viral load |
| 2 | Viral hepatitis B |
| 2 | Vietnam |
| 2 | Vector |
| 2 | Vaccines, Attenuated |
| 2 | Vaccination (economics) |
| 2 | Typing |
| 2 | Tuberculosis |
| 2 | Travel (statistics & numerical data) |
| 2 | Toxoplasma gondii |
| 2 | Time to the most recent common ancestor (TMRCA) |
| 2 | Sustainability |
| 2 | Surveys and Questionnaires |
| 2 | Sub-Saharan Africa |
| 2 | Streptococcus pneumoniae |
| 2 | Strategy |
| 2 | Statin derivative |
| 2 | Spoligotyping |
| 2 | Spanish flu |
| 2 | South east Asia |
| 2 | Solvency II |
| 2 | Simulation model |
| 2 | Sequence analysis |
| 2 | Sequence Analysis, DNA |
| 2 | Sequence Alignment |
| 2 | Selection pressure |
| 2 | Schools (organization & administration) |
| 2 | School environment |
| 2 | SIV |
| 2 | SIR model |
| 2 | SARS-CoV |
| 2 | Rimantadine (therapeutic use) |
| 2 | Rheumatology |
| 2 | Respiratory system infection |
| 2 | Respiratory support |
| 2 | Respiratory Tract Infections (epidemiology) |
| 2 | Respiratory Distress Syndrome, Adult (mortality) |
| 2 | Respiration, Artificial (methods) |
| 2 | Reservoir |
| 2 | Research and development |
| 2 | Reassortant Viruses (physiology) |
| 2 | Rapid technique |
| 2 | RNA Replicase (metabolism) |
| 2 | RNA Replicase (genetics) |
| 2 | Quantitative analysis |
| 2 | Pulmonary Disease, Chronic Obstructive (epidemiology) |
| 2 | Public Opinion |
| 2 | Public Health (methods) |
| 2 | Psycholinguistics |
| 2 | Protein Precursors (blood) |
| 2 | Protective mask |
| 2 | Protection Insurance |
| 2 | Probability |
| 2 | Primary care |
| 2 | Preparation |
| 2 | Pregnancy Outcome |
| 2 | Pregnancy Complications, Infectious (virology) |
| 2 | Pregnancy Complications, Infectious (prevention & control) |
| 2 | Pregnancy Complications, Infectious (epidemiology) |
| 2 | Predictive factor |
| 2 | Prediction |
| 2 | Practice Guidelines as Topic |
| 2 | Poverty |
| 2 | Population surveillance |
| 2 | Polymerase Chain Reaction |
| 2 | Policy Making |
| 2 | Pneumopathy |
| 2 | Pneumonia (virology) |
| 2 | Pneumococcal infection |
| 2 | Planning |
| 2 | Plague |
| 2 | Picornaviridae Infections (epidemiology) |
| 2 | Phylogenetic analysis |
| 2 | Phylogenetic analyses |
| 2 | Phase III trial |
| 2 | Pharmacovigilance |
| 2 | Peptides (immunology) |
| 2 | Peptides (chemistry) |
| 2 | Patient Acceptance of Health Care |
| 2 | Pandemics (history) |
| 2 | Pandemic influenza A/H1N1 |
| 2 | Overlapping genes |
| 2 | Outbreak |
| 2 | Orthomyxoviridae Infections (virology) |
| 2 | Orthomyxoviridae Infections (immunology) |
| 2 | Orthomyxoviridae (pathogenicity) |
| 2 | Orthomyxoviridae (immunology) |
| 2 | Organization |
| 2 | On line |
| 2 | Occupational medicine |
| 2 | Occupational exposure |
| 2 | Neutralizing antibodies |
| 2 | Network |
| 2 | Neonatal |
| 2 | Mutation (genetics) |
| 2 | Multiplex polymerase chain reaction |
| 2 | Mortalité |
| 2 | Mortality Risk |
| 2 | Molecular epidemiology |
| 2 | Molecular Sequence Data |
| 2 | Models, Immunological |
| 2 | Modelling |
| 2 | Model |
| 2 | Mobility |
| 2 | Mice, Inbred BALB C |
| 2 | Mexico (epidemiology) |
| 2 | Method |
| 2 | Metapopulation |
| 2 | Mechanical ventilation |
